- As FG unveils seven herbal medicines, scientists push to turn Nigeria’s biodiversity into a pharmaceutical industry
For centuries, Nigerians have relied on leaves, roots, bark and herbs to treat illnesses passed down through generations of traditional healers. Today, the Federal Government is seeking to move many of those remedies from folklore into the laboratory, unveiling seven indigenous herbal medicines as part of a broader effort to build a modern pharmaceutical industry rooted in the country’s vast biodiversity.
The medicines, developed by the Nigeria Natural Medicine Development Agency (NNMDA), are intended for the treatment or management of prostate cancer, colorectal cancer, peptic ulcer disease, hepatitis B, hypertension and high cholesterol. They form part of more than 22 herbal products the agency says it has developed since 2023 from locally sourced medicinal plants to address diseases affecting millions of Nigerians.
Their unveiling in Lagos signals an ambition that extends well beyond healthcare. If successfully validated, manufactured and commercialised, indigenous medicines could reduce Nigeria’s heavy dependence on imported pharmaceuticals, strengthen local drug production, create new industries and open export opportunities in a global herbal medicine market valued in hundreds of billions of dollars.
Launching the products during a visit to the agency, the Minister of Innovation, Science and Technology, Dr. Kingsley Udeh, described Nigeria’s rich plant biodiversity as one of the country’s greatest but least exploited scientific assets. He said medicinal plants have supported healthcare delivery for generations, adding that modern science now provides an opportunity to standardise, validate and commercialise many of those natural remedies through evidence-based research.
The minister announced plans to facilitate the establishment of a Clinical Observational Research Centre to strengthen scientific studies on indigenous medicines, explaining that the Federal Government would explore alternative funding sources rather than wait for the 2027 budget cycle before commencing the project.
He also commended the agency’s expanding research into natural therapies for diseases including malaria, sickle cell disease, diabetes and erectile dysfunction, expressing confidence that locally developed medicines could become an important contributor to economic diversification while improving access to affordable healthcare.
Nigeria possesses one of Africa’s richest collections of medicinal plants, yet much of that natural wealth remains scientifically underexplored. Researchers have long argued that the country’s biodiversity offers opportunities not only for healthcare but also for pharmaceutical innovation, provided discoveries are subjected to rigorous laboratory research, clinical evaluation and internationally recognised quality standards.
Director-General of the NNMDA, Prof. Martins Emeje, said advances in pharmaceutical standardisation have significantly improved the consistency, quality and dosage of the agency’s herbal formulations, enabling them to be produced in modern dosage forms including capsules, tablets and syrups.
Among the products introduced are Namdavir, developed for hepatitis B; Namdacid, for peptic ulcer disease; Turmegol, intended for the management of colorectal, ovarian and prostate cancers; Namdorol, for hypertension and high cholesterol; Namgor, an herbal aphrodisiac; and Zobo Tea, formulated to support hypertension management.
Emeje said the agency’s long-term objective is to position Nigeria not merely as a consumer of medicines developed elsewhere but as a producer and exporter of high-quality natural pharmaceutical products. He estimated that the commercialisation of one of the newly developed medicines alone could generate as many as 3.5 million jobs across cultivation, harvesting, processing, manufacturing, packaging, distribution and related value chains.
He renewed the agency’s call for the establishment of a Clinical Observational Research Centre at its Lagos headquarters, arguing that stronger investment in clinical research would accelerate the scientific validation of indigenous medicines and improve their acceptance within Nigeria and internationally.
The initiative also drew international attention. India’s Consul General in Lagos, Shri Kannan, proposed deeper collaboration between both countries in medicinal plant research, scientific validation, biodiversity conservation, quality assurance, academic exchange and pharmaceutical innovation. India has emerged as one of the world’s leading producers of traditional medicines through the integration of indigenous knowledge with modern scientific research and regulatory systems.
Public health specialists have consistently maintained that the future of herbal medicine depends not only on centuries of traditional use but also on rigorous scientific evidence. In Nigeria, herbal products intended for therapeutic use are subject to regulation by the National Agency for Food and Drug Administration and Control (NAFDAC), which requires manufacturers to demonstrate quality, safety and efficacy before products are approved for public use.
That regulatory process will remain central as Nigeria seeks to expand indigenous pharmaceutical research. Scientific validation, transparent clinical studies and strict quality control will ultimately determine whether locally developed herbal medicines gain the confidence of doctors, researchers, investors and patients.
The country’s forests and savannahs have long sustained traditional medicine. The challenge before scientists today is to transform that botanical wealth into medicines that satisfy modern pharmaceutical standards while creating jobs, strengthening healthcare and reducing dependence on imported drugs. If that ambition succeeds, Nigeria’s biodiversity could become more than a natural inheritance; it could form the foundation of one of the country’s next major knowledge-driven industries.













